

I hereby certify that this correspondence is being deposited with the United States Postal Service as First-Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on September 27, 2006

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

ITW

INFORMATION DISCLOSURE
STATEMENT

Examining Group 1632
Patent Application
Docket No. USF-183XC1
Serial No. 10/526,584

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : (Not yet assigned)
Art Unit : 1632
Applicant : Shyam S. Mohapatra
Serial No. : 10/526,584
Filed : March 3, 2005
For : Materials and Methods for Treatment of Allergic Diseases

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, the applicant has not submitted copies of the U.S. patents or published U.S. applications cited on attached Form PTO/SB/08 pursuant to 37 C.F.R. §1.98(a)(2)(ii).

The applicant respectfully asserts that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Glenn P. Ladwig

Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800


Address: P.O. Box 142950

Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (8 pages); copies of some references cited therein

J:\USF\183XC1\PTOIDS.pto.doc\DNB/mv



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/526,584
				Filing Date	March 3, 2005
				First Named Inventor	Shyam S. Mohapatra
				Art Unit	1632
				Examiner Name	
Sheet	1	of	8	Attorney Docket Number	USF-183XC1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-6,943,147	09-13-2005	Vesely	All
	U2	US-5,691,310	11-25-1997	Vesely	All
	U3	US-5,840,341	11-24-1998	Watts et al.	All
	U4	US-2006/0110359 A1	05-25-2006	Sanchez-Ramos et al.	All
	U5	US-2006/0014689 A1	01-19-2006	Vesely	All
	U6	US-2005/0272650 A1	12-08-2005	Mohapatra	All
	U7	US-2005/0209139 A1	09-22-2005	Vesely	All
	U8	US-2005/0014289 A1	01-20-2005	Parsons et al.	All
	U9	US-2005/0014287 A1	01-20-2005	Friese et al.	All
	U10	US-2004/0266673 A1	12-30-2004	Bakis et al.	All
	U11	US-2004/0224903 A1	11-11-2004	Berry et al.	All

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1	WO 2005/094420 A2	10-13-2005	Univ. of South Florida	All	
	F					
	F					
	F					
	F					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/526,584	
			Filing Date	March 3, 2005	
			First Named Inventor	Shyam S. Mohapatra	
			Art Unit	1632	
			Examiner Name		
Sheet	2	of	8	Attorney Docket Number	USF-183XC1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U12	US-2004/0213782 A1	10-28-2004	Wax et al.	All
	U13	US-2004/0203081 A1	10-14-2004	James et al.	All
	U14	US-2004/0171550 A1	09-02-2004	Backstrom et al.	All
	U15	US-2004/0146549 A1	07-29-2004	Ben-Sasson et al.	All
	U16	US-2004/0138134 A1	07-15-2004	Golembo et al.	All
	U17	US-2004/0067889 A1	04-08-2004	Belenky et al.	All
	U18	US-2004/0002458 A1	01-01-2004	Seilhamer et al.	All
	U19	US-2003/0204063 A1	10-30-2003	Gravel et al.	All
	U20	US-2003/0147943 A1	08-07-2003	Luo et al.	All
	U21	US-2003/0073628 A1	04-17-2003	Shailubhai et al.	All
	U22	US-2003/0069186 A1	04-10-2003	Burnett et al.	All
	U23	US-2001/0027181 A1	10-04-2001	Kitakaze et al.	All

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F					
	F					
	F					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/526,584
				Filing Date	March 3, 2005
				First Named Inventor	Shyam S. Mohapatra
				Group Art Unit	1632
				Examiner Name	
Sheet	3	of	8	Attorney Docket Number	USF-183XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	ABBEY, S. and POTTER, L. "Lysophosphatidic acid inhibits C-type natriuretic peptide activation of guanylyl cyclase-B" <i>Endocrinology</i> , 2003, 144:240-246.	
	R2	ANGUS, R.M. <i>et al.</i> "Effect of inhaled atrial natriuretic peptide on methacholine induced bronchoconstriction in asthma" <i>Clin Exp Allergy</i> 1994, 24:784-788.	
	R3	ANGUS, R.M. <i>et al.</i> "Effect of inhaled atrial natriuretic peptide and a neutral endopeptidase inhibitor on histamine-induced bronchoconstriction" <i>Am. J. Respir. Crit. Care Med.</i> , 1995, 151:2003-2005.	
	R4	BLISS, D. <i>et al.</i> "Expression of the atrial natriuretic factor gene in small cell lung cancer tumors and tumor cell lines" <i>J Natl Can Inst</i> , 1990, 82:305-310.	
	R5	BOITEAU, R. <i>et al.</i> "Increase in atrial natriuretic factor (ANF) in acute severe asthma (ASA)" <i>Am Rev Res Dis.</i> , 1988, 137:A484.	
	R6	CHANEZ, P. <i>et al.</i> "Atrial natriuretic factor (ANF) is a potent bronchodilator in asthma" <i>J. Allergy Clin. Immunol.</i> , 1990, 86:321-324.	
	R7	CHEN, S. <i>et al.</i> "1,25 dihydroxyvitamin D amplifies type A natriuretic peptide receptor expression and activity in target cells" <i>J. Am. Soc. Nephrol.</i> , 2005, 16:329-339.	
	R8	DELPORTE, C. <i>et al.</i> "Discovery of a potent atrial natriuretic peptide antagonist for ANP _A receptors in the human neuroblastoma NB-OK-1 cell line" <i>Eur. J. Pharmacol.</i> , 1992, 224(2-3):183-188.	
	R9	DREWETT, J.G. and GARBERS, D.L. "The family of guanylyl cyclase receptors and their ligands" <i>Endocrine Reviews</i> , 1994, 15(2):135-162.	
	R10	EL-AYOUBI, R. <i>et al.</i> "Urinary responses to acute moxonidine are inhibited by natriuretic peptide receptor antagonist" <i>Br. J. Pharmacol.</i> , 2005, 145:50-56.	
	R11	ERNST, P. "Review article: the role of inflammation in the pathogenesis of gastric cancer" <i>Aliment Pharmacol Ther.</i> , 1999, 13(1):13-18.	
	R12	FONAROW, G.C. <i>et al.</i> "Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure" <i>Rev. Cardiovasc. Med.</i> , 2003, 4(suppl 4):S20-S28.	
	R13	FUJISEKI, Y. <i>et al.</i> "Natriuretic peptide receptors, NPR-A and NPR-B, in cultured rabbit retinal pigment epithelium cells" <i>Jpn. J. Pharmacol.</i> , 1999, 79(3):359-368.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/526,584
				Filing Date	March 3, 2005
				First Named Inventor	Shyam S. Mohapatra
				Group Art Unit	1632
				Examiner Name	
Sheet	4	of	8	Attorney Docket Number	USF-183XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R14	FÜRST, R. <i>et al.</i> "Atrial natriuretic peptide induces mitogen-activated protein kinase phosphatase-1 in human endothelial cells via Rac1 and NAD(P)H oxidase/Nox2-activation" <i>Circ. Res.</i> , 2005, 96:43-53.	
	R15	GOWER, W.R. <i>et al.</i> "Regulation of atrial natriuretic peptide secretion by cholinergic and PACAP neurons of the gastric antrum" <i>Am. J. Physiol. Gastrointest. Liver Physiol.</i> , 2003, 284:G68-G74.	
	R16	GREENBERG, B.D. <i>et al.</i> "Nucleotide sequence of the gene encoding human atrial natriuretic factor precursor" <i>Nature</i> , 1984, 312(5995):656-658.	
	R17	GRETEN, F.R. <i>et al.</i> "IKK β links inflammation and tumorigenesis in a mouse model of colitis-associated cancer" <i>Cell</i> , 2004, 118:285-296.	
	R18	HAMET, P. and TREMBLAY, J. "Aspects physiologiques et physiopathologiques du facteur natriuretique auriculaire" <i>Nephrologie</i> , 1987, 8:7-12, abstract.	
	R19	HULKS, G. <i>et al.</i> "Effect of atrial natriuretic factor on bronchomotor tone in the normal human airway" <i>Clin Sci</i> 1990;79:51-55.	
	R20	HULKS, G. and THOMSON, N.C. "High dose inhaled atrial natriuretic peptide is a bronchodilator in asthmatic subjects" <i>Eur. Respir. J.</i> , 1994, 7:1593-1597.	
	R21	HULKS, G. and THOMSON, N.C. "Inhaled atrial natriuretic peptide and asthmatic airways" <i>Br. Med J</i> , 1992, 304:1156.	
	R22	ISHII, Y. <i>et al.</i> "Effects of atrial natriuretic peptide on Type II alveolar epithelial cells of the rat lung. Autoradiographic and morphometric studies" <i>J Anat.</i> , 1989, 166:85-95.	
	R23	IZUMI, T. <i>et al.</i> "Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF- κ B activation and alleviates myocardial ischemia/reperfusion injury" <i>J Clin Invest</i> 2001, 108:203-213.	
	R24	JIN, H. <i>et al.</i> "Novel analog of atrial natriuretic peptide selective for receptor-A produces increased diuresis and natriuresis in rats" <i>J. Clin. Invest.</i> , 1996, 98:969-976.	
	R25	KANWAL, S. <i>et al.</i> "Intracellular fragments of the natriuretic peptide receptor-C (NPR-C) attenuate dopamine efflux" <i>Endocrinology</i> , 1999, 140(3):1118-1124.	
	R26	KELLY, R. and STRUTHERS, A. "Are natriuretic peptides clinically useful as markers of heart failure?" <i>Ann. Clin. Biochem.</i> , 2001, 38:94-102.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/526,584
				Filing Date	March 3, 2005
				First Named Inventor	Shyam S. Mohapatra
				Group Art Unit	1632
				Examiner Name	
Sheet	5	of	8	Attorney Docket Number	USF-183XC1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R27	KHURANA, M.L. and PANDEY, K.N. "Receptor-mediated stimulatory effect of atrial natriuretic factor, brain natriuretic peptide, and C-type natriuretic peptide on testosterone production in purified mouse Leydig cells: Activation of cholesterol side-chain cleavage enzyme" <i>Endocrinology</i> , 1993, 133:2141-2149.	
	R28	KIEMER, A. and VOLLMAR, A. "Autocrine regulation of inducible nitric-oxide synthase in macrophages by atrial natriuretic peptide" <i>J Biol Chem</i> , 1998, 273:13444-13451.	
	R29	KIEMER, A. <i>et al.</i> "cGMP-mediated inhibition of TNF- α production by the atrial natriuretic peptide in murine macrophages" <i>J Immunol</i> , 2000, 165:175-181.	
	R30	KUMAR, R. <i>et al.</i> "Expression of guanylyl cyclase-A/atrial natriuretic peptide receptor blocks the activation of protein kinase C in vascular smooth muscle cells" <i>Hypertension</i> , 1997, 29(part 2):414-421.	
	R31	KUMAR, M. <i>et al.</i> "Intranasal IFN- γ gene transfer protects BALB/c mice against respiratory syncytial virus infection" <i>Vaccine</i> 1999; 18:558-567.	
	R32	KUMAR, M <i>et al.</i> "Atrial natriuretic peptide gene transfer by means of intranasal administration attenuates airway reactivity in a mouse model of allergic sensitization" <i>J Allergy Clin Immunol.</i> , 2002, 110:879-882.	
	R33	KURIHARA, M. <i>et al.</i> "Lower number of atrial natriuretic peptide receptors in thymocytes and spleen cells of spontaneously hypertensive rats" <i>Biochem Biophys Res Commun</i> 1987, 149:1132-1140.	
	R34	LIANG, F. <i>et al.</i> "Sp1 dependence of natriuretic peptide receptor A gene transcription in rat aortic smooth muscle cells" <i>Endocrinology</i> , 1999, 140(4):1695-1701.	
	R35	LOUZIER, V. <i>et al.</i> "Adenovirus-mediated atrial natriuretic protein expression in the lung protects rats from hypoxia-induced pulmonary hypertension" <i>Hum Gene Ther</i> , 2001, 12:503-513.	
	R36	MAISEL, A.S. <i>et al.</i> "Cardiac natriuretic peptides: A proteomic window to cardiac function and clinical management" <i>Rev. Cardiovasc. Med.</i> , 2003, 4(suppl 4):S3-S12.	
	R37	MARTIN, J. <i>et al.</i> "Modulation by biologic response modifiers of hepatitis C virus antigen-independent cytokine secretion in blood mononuclear cells" <i>Cytokine</i> , 1999, 11:267-273.	
	R38	MATANIĆ, D. <i>et al.</i> "Cytokines in patients with lung cancer" <i>Scand J Immunol</i> , 2003, 57:173-178.	
	R39	MATSUKAWA, N. <i>et al.</i> "The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system" <i>Proc. Natl. Acad. Sci. USA</i> , 1999, 96:7403-7408.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/526,584
				Filing Date	March 3, 2005
				First Named Inventor	Shyam S. Mohapatra
				Group Art Unit	1632
				Examiner Name	
				Attorney Docket Number	USF-183XC1
Sheet	6	of	8		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R40	MATSUSE, H. <i>et al.</i> "Recurrent respiratory syncytial virus infections in allergen-sensitized mice lead to persistent airway inflammation and hyperresponsiveness" <i>J Immunol</i> , 2000, 164:6583-6592.	
	R41	MOHAPATRA, S. <i>et al.</i> "Natriuretic peptides and genesis of asthma: An emerging paradigm?" <i>J Allergy Clin Immunol</i> , 2004, 114:520-526.	
	R42	MOTOHASHI, S. <i>et al.</i> "Preserved IFN- α production of circulating Va24 NKT cells in primary lung cancer patients" <i>Int J Cancer</i> , 2002, 102:159-165.	
	R43	MUELLER, C. and BUSER, P. "B-type natriuretic peptide (BNP): can it improve our management of patients with congestive heart failure?" <i>Swiss Med Wkly</i> , 2002, 132:618-622.	
	R44	NAKAGAWA, K. <i>et al.</i> "Plasma concentrations of atrial and brain natriuretic peptides in a case with hypertensive encephalopathy" <i>Neurol. Res.</i> , 2002, 24:627-630.	
	R45	NAZARIO, B. <i>et al.</i> "Atrial and brain natriuretic peptides stimulate the production and secretion of C-type natriuretic peptide from bovine aortic endothelial cells" <i>J. Clin. Invest.</i> , 1995, 95:1151-1157.	
	R46	NEEDLEMAN, P. and GREENWALD, J.E. "Atriopeptin: a cardiac hormone intimately involved in fluid, electrolyte, and blood-pressure homeostasis" <i>N Engl J Med</i> , 1986, 314:828-834.	
	R47	OHBAIYASHI, H. <i>et al.</i> "Compared effects of natriuretic peptides on ovalbumin-induced asthmatic model" <i>Eur. J. Pharmac.</i> , 1998, 346:55-64.	
	R48	OHSAKI, Y. <i>et al.</i> "Human small cell lung cancer cell lines express functional atrial natriuretic peptide receptors" <i>Cancer Res</i> , 1993, 53:3165-3171.	
	R49	OHSAKI, Y. <i>et al.</i> "Human small cell lung cancer cells produce brain natriuretic peptide" <i>Oncology</i> , 1999, 56:155-159.	
	R50	OHYAMA, Y. <i>et al.</i> "Stable expression of natriuretic peptide receptors: Effects of HS-142-1, a non-peptide ANP antagonist" <i>Biochem. Biophys. Res. Commun.</i> , 1992, 189(1):336-342.	
	R51	PANDEY, K.N. <i>et al.</i> "Natriuretic peptide receptor-A negatively regulates mitogen-activated protein kinase and proliferation of mesangial cells: Role of cGMP-dependent protein kinase" <i>Biochem. Biophys. Res. Commun.</i> , 2000, 271(2):374-379.	
	R52	PANDEY, K.N. <i>et al.</i> "Internalization and trafficking of guanylyl (guanylate) cyclase/natriuretic peptide receptor A is regulated by an acidic tyrosine-based cytoplasmic motif GDAY" <i>Biochem. J.</i> , 2005, 388:103-113.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/526,584
				Filing Date	March 3, 2005
				First Named Inventor	Shyam S. Mohapatra
				Group Art Unit	1632
				Examiner Name	
Sheet	7	of	8	Attorney Docket Number	USF-183XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R53	PANDEY, K.N. <i>et al.</i> "Ligand-regulated internalization, trafficking, and down-regulation of guanylyl cyclase/atrial natriuretic peptide receptor-A in human embryonic kidney 293 cells" <i>J. Biol. Chem.</i> , 2002, 277(7):4618-4627.	
	R54	PANDEY, K.N. <i>et al.</i> "Functional domains and expression of truncated atrial natriuretic peptide receptor-A: The carboxyl-terminal regions direct the receptor internalization and sequestration in COS-7 cells" <i>Molecular Pharmacology</i> , 2000, 57:259-267.	
	R55	PANDEY, K.N. "Dynamics of internalization and sequestration of guanylyl cyclase/atrial natriuretic peptide receptor-A" <i>Can. J. Physiol. Pharmacol.</i> , 2001, 79(8):631-639.	
	R56	PANDEY, K.N. "Intracellular trafficking and metabolic turnover of ligand-bound guanylyl cyclase/atrial natriuretic peptide receptor-A into subcellular compartments" <i>Mol. Cell. Biochem.</i> , 2002, 230(1-2):61-72.	
	R57	PIKARSKY, E. <i>et al.</i> "NF- κ B functions as a tumour promoter in inflammation-associated cancer" <i>Nature</i> , 2004, 431:461-466.	
	R58	PRINS, B.A. <i>et al.</i> "Atrial natriuretic peptide inhibits mitogen-activated protein kinase through the clearance receptor" <i>J. Biol. Chem.</i> , 1996, 271(24):14156-14162.	
	R59	ROULEAU, N. <i>et al.</i> "Development of a Non-radioactive Homogenous HTS Platform to Measure the Activity of Guanylate Cyclase", Poster #P10144, Presented at 10 th Annual SBS Conference and Exhibition, Orlando, FL, September 11-15, 1004, PERKINELMER BIOSIGNAL Inc., Canada.	
	R60	ROY, K. <i>et al.</i> "Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy" <i>Nat Med</i> , 1999, 5:387-391.	
	R61	RUTHERFORD, R. <i>et al.</i> "Identification of renal natriuretic peptide receptor subpopulations by use of the non-peptide antagonist, HS-142-1" <i>Br. J. Pharmacol.</i> , 1994, 113:931-939.	
	R62	SEIDMAN, C.E. <i>et al.</i> "The structure of rat preproatrial natriuretic factor as defined by a complementary DNA clone" <i>Science</i> , 1984, 225:324-326.	
	R63	SEIDMAN, C.E. <i>et al.</i> "Nucleotide sequences of the human and mouse atrial natriuretic factor genes" <i>Science</i> , 1984, 226:1206-1209.	
	R64	SEKIGUCHI, T. <i>et al.</i> "Molecular cloning of natriuretic peptide receptor A from bullfrog (<i>Rana catesbeiana</i>) brain and its functional expression" <i>Gene</i> , 2001, 273:251-257.	
	R65	SHARMA, G.D. <i>et al.</i> "Expression of atrial natriuretic peptide receptor-A antagonizes the mitogen-activated protein kinases (Erk2 and P38 ^{MAPK}) in cultured human vascular smooth muscle cells" <i>Mol. Cell. Biochem.</i> , 2002, 233(1-2):pages 165-173.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/526,584	
			Filing Date	March 3, 2005	
			First Named Inventor	Shyam S. Mohapatra	
			Group Art Unit	1632	
			Examiner Name		
Sheet	8	of	8	Attorney Docket Number	USF-183XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R66	SHI, S-J. <i>et al.</i> "Natriuretic peptide receptor A mediates renal sodium excretory responses to blood volume expansion" <i>Am. J. Physiol. Renal Physiol.</i> , 2003, 285:F694-F702.	
	R67	SHIMIZU, K. <i>et al.</i> "Ectopic atrial natriuretic peptide production in small cell lung cancer with the syndrome of inappropriate antidiuretic hormone secretion" <i>Cancer</i> 1991, 68:2284-2288.	
	R68	SILBERBACH, M. and ROBERTS JR., C. "Natriuretic peptide signaling molecular and cellular pathways to growth regulation" <i>Cell Signal</i> , 2001, 13:221-231.	
	R69	SIMKINS, J. "Nesiritide (Natrecor®) for Decompensated CHF" in The University of Montana's School of Pharmacy and Allied Health Sciences Drug Information Service, April 2002, Vol. 6 No. 4.	
	R70	SUENOBU, N. <i>et al.</i> "Natriuretic peptides and nitric oxide induce endothelial apoptosis via a cGMP-dependent mechanism" <i>Arterioscler Thromb Vasc Biol.</i> , 1999, 19:140-146.	
	R71	SURIC-LAMBIC, L. <i>et al.</i> "Vasoactive natriuretic peptides and kidney" <i>Facta Universitatis: Medicine and Biology</i> , 1998, 5(1):6-11.	
	R72	TRUE, D. <i>et al.</i> "Comparison of Kinase Assay Technologies for High Throughput Screening" poster presented at Society for Biomolecular Screening (SBS), 8 th Annual Conference, September 22-26, 2002.	
	R73	VESELY, B.A. <i>et al.</i> "Four peptides decrease the number of human pancreatic adenocarcinoma cells" <i>Eur. J. Clin. Invest.</i> , 2003, 33:998-1005.	
	R74	VESELY, D.L. "Atrial natriuretic peptides in pathophysiological diseases" <i>Cardiovascular Res.</i> , 2001, 51:647-658.	
	R75	WANG, W. <i>et al.</i> "AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure" <i>Pharm. Res.</i> , 2004, 21(11):2105-2111.	
	R76	WINQUIST, R. <i>et al.</i> "Atrial natriuretic factor elicits an endothelium-independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle" <i>Proc. Natl. Acad. Sci. USA</i> , 1984, 81:7661-7664.	
	R		
	R		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.